Eating Disorder

Categories: Mental diseases, Metabolic diseases, Neuronal diseases

Aliases & Classifications for Eating Disorder

MalaCards integrated aliases for Eating Disorder:

Name: Eating Disorder 12 15 17
Eating Disorders 37 55 43 15 72 33
Feeding and Eating Disorders 44


External Ids:

Disease Ontology 12 DOID:8670
KEGG 37 H01703
ICD9CM 35 307.50
MeSH 44 D001068
NCIt 50 C89332
SNOMED-CT 68 72366004
ICD10 33 F50 F50.9
UMLS 72 C0013473

Summaries for Eating Disorder

KEGG : 37
Eating disorders, which include anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED), are disorders defined by disturbances in eating behavior. Anorexia nervosa (AN) is the oldest recognized eating disorder. The salient features of this eating disorder are a relentless pursuit of thinness, accompanied by a fear of becoming fat despite being markedly underweight. In women, anorexia nervosa is associated with global endocrine dysregulation, including hypothalamic-pituitary axis dysfunction and alterations in adipokine and appetite regulating hormone levels. Bulimia nervosa (BN) is defined by eating behaviors that include episodes of binge eating which are followed by recurrent self-induced vomiting performed in an attempt to avoid weight gain from the caloric overload. Binge eating disorder (BED) is currently characterized by recurrent episodes of binge eating occurring at least twice a week for 6 months or longer. In contrast to bulimia nervosa, there are no inappropriate compensatory behaviors such as vomiting. Eating disorders frequently develop during adolescence or early adulthood, but some studies have reported their onset during childhood or later in adulthood. There is growing evidence supporting a multifactorial etiology that includes genetic, neurochemical, and physiological components for eating disorders above and beyond the more conventional theories based on psychological and sociocultural factors. Brain-derived neurotrophic factor (BDNF) plays a critical role in regulating nerves in the brain. Recent studies have provided evidence that BDNF also plays a role in regulating eating behaviors. In addition, an association between the BDNF gene polymorphism and eating disorders has been demonstrated. Other genetic risk factors for eating disorders has also been reported.

MalaCards based summary : Eating Disorder, also known as eating disorders, is related to borderline personality disorder and gastroparesis, and has symptoms including decrease in appetite, adipsia and symptoms concerning nutrition, metabolism, and development. An important gene associated with Eating Disorder is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are Adipocytokine signaling pathway and cAMP signaling pathway. The drugs Zinc and Zinc sulfate have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health.

MedlinePlus : 43 Eating disorders are serious behavior problems. They can include severe overeating or not consuming enough food to stay healthy. They also involve extreme concern about your shape or weight. Types of eating disorders include Anorexia nervosa, in which you become too thin, but you don't eat enough because you think you are fat Bulimia nervosa, which involves periods of overeating followed by purging, sometimes through self-induced vomiting or using laxatives Binge-eating, which is out-of-control eating Women are more likely than men to have eating disorders. They usually start in the teenage years and often occur along with depression, anxiety disorders, and substance abuse. Eating disorders can lead to heart and kidney problems and even death. Getting help early is important. Treatment involves monitoring, talk therapy, nutritional counseling, and sometimes medicines. NIH: National Institute of Mental Health

Wikipedia : 75 An eating disorder is a mental disorder defined by abnormal eating habits that negatively affect a... more...

Related Diseases for Eating Disorder

Diseases related to Eating Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)
# Related Disease Score Top Affiliating Genes
1 borderline personality disorder 32.4 SLC6A4 HTR2C COMT BDNF
2 gastroparesis 32.4 GHRL DRD2 CCK
3 bulimia nervosa 32.4 SLC6A4 PYY NPY MC4R LEP GHRL
4 alexithymia 31.6 SLC6A4 DRD2 COMT
5 social phobia 31.2 SLC6A4 DRD2 CCK
6 amenorrhea 31.0 POMC LEP CRH
7 depression 31.0 SLC6A4 HTR2C CRH BDNF
8 constipation 30.8 SLC6A4 PYY NPY CCK
9 personality disorder 30.7 SLC6A4 SLC6A3 HTR2C DRD2 COMT BDNF
10 dyspepsia 30.7 SLC6A4 GHRL CCK
11 bipolar disorder 30.7 SLC6A4 SLC6A3 DRD2 COMT BDNF
12 substance abuse 30.6 SLC6A4 SLC6A3 NPY DRD2 COMT BDNF
13 gastroesophageal reflux 30.6 PYY GHRL CCK
14 generalized anxiety disorder 30.6 SLC6A4 DRD2 COMT BDNF
15 pathological gambling 30.6 SLC6A4 SLC6A3 DRD2
16 polysubstance abuse 30.5 DRD2 COMT CNR1
17 postpartum depression 30.5 SLC6A4 CRH COMT BDNF
18 traumatic brain injury 30.4 DRD2 COMT BDNF
19 brain injury 30.4 DRD2 COMT BDNF
20 cocaine abuse 30.3 SLC6A4 SLC6A3 DRD2
21 fibromyalgia 30.3 SLC6A4 NPY CRH COMT
22 oppositional defiant disorder 30.3 SLC6A4 SLC6A3 DRD2 COMT
23 endogenous depression 30.3 SLC6A4 NPY CRH BDNF
24 migraine with or without aura 1 30.2 SLC6A4 HTR2C DRD2 COMT CNR1
25 tobacco addiction 30.2 SLC6A4 SLC6A3 DRD2 COMT
26 alcoholic psychosis 30.1 SLC6A4 SLC6A3 DRD2
27 sleep apnea 30.0 LEPR LEP GHRL ADIPOQ
28 periodic limb movement disorder 30.0 SLC6A4 HTR2C DRD2
29 antisocial personality disorder 30.0 SLC6A4 SLC6A3 DRD2 COMT
30 conduct disorder 30.0 SLC6A4 SLC6A3 DRD2 COMT
31 mental depression 30.0 SLC6A4 POMC HTR2C CRH COMT BDNF
32 schizoaffective disorder 29.9 SLC6A4 DRD2 COMT BDNF
33 gilles de la tourette syndrome 29.9 SLC6A3 DRD2 COMT BDNF
34 panic disorder 29.9 SLC6A4 POMC CRH COMT CCK
35 major depressive disorder 29.8 SLC6A4 SLC6A3 POMC NPY HTR2C DRD2
36 attention deficit-hyperactivity disorder 29.8 SLC6A4 SLC6A3 NPY HTR2C DRD2 COMT
37 kleine-levin hibernation syndrome 29.8 SLC6A3 POMC COMT
38 withdrawal disorder 29.8 POMC CRH CNR1
39 post-traumatic stress disorder 29.7 SLC6A4 DRD2 CRH COMT CNR1 BDNF
40 substance dependence 29.7 SLC6A4 SLC6A3 POMC DRD2 CNR1 BDNF
41 obsessive-compulsive disorder 29.7 SLC6A4 SLC6A3 HTR2C DRD2 CRH COMT
42 psychotic disorder 29.6 SLC6A4 SLC6A3 HTR2C DRD2 COMT BDNF
43 gastrointestinal system disease 29.5 PYY GHRL CRH CCK
44 chronic fatigue syndrome 29.4 SLC6A4 POMC CRH COMT
45 fatty liver disease 29.3 LEPR LEP ADIPOQ
46 irritable bowel syndrome 29.3 SLC6A4 PYY CRHR2 CRH CCK
47 mood disorder 29.3 SLC6A4 POMC NPY HTR2C DRD2 CRH
48 anorexia nervosa 29.2 SLC6A4 PYY POMC NPY MC4R LEPR
49 glucose intolerance 29.1 LEPR LEP GHRL ADIPOQ
50 anxiety 29.0 SLC6A4 NPY HTR2C CRHR2 CRH COMT

Comorbidity relations with Eating Disorder via Phenotypic Disease Network (PDN):

Major Depressive Disorder

Graphical network of the top 20 diseases related to Eating Disorder:

Diseases related to Eating Disorder

Symptoms & Phenotypes for Eating Disorder

UMLS symptoms related to Eating Disorder:

decrease in appetite, adipsia, symptoms concerning nutrition, metabolism, and development

MGI Mouse Phenotypes related to Eating Disorder:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.54 ADIPOQ BDNF CNR1 COMT CRH CRHR2
2 homeostasis/metabolism MP:0005376 10.49 ADIPOQ BDNF CCK CNR1 COMT CRH
3 adipose tissue MP:0005375 10.4 ADIPOQ CNR1 CRH CRHR2 DRD2 GHRL
4 growth/size/body region MP:0005378 10.39 ADIPOQ BDNF CNR1 CRH DRD2 HTR2C
5 endocrine/exocrine gland MP:0005379 10.37 ADIPOQ BDNF CCK COMT CRH CRHR2
6 nervous system MP:0003631 10.36 ADIPOQ BDNF CCK CNR1 COMT CRH
7 immune system MP:0005387 10.26 ADIPOQ COMT CRH CRHR2 DRD2 HTR2C
8 integument MP:0010771 10.25 ADIPOQ BDNF CNR1 CRH DRD2 HTR2C
9 cardiovascular system MP:0005385 10.23 ADIPOQ COMT CRHR2 DRD2 LEP LEPR
10 digestive/alimentary MP:0005381 10.11 BDNF CNR1 DRD2 GHRL LEP LEPR
11 normal MP:0002873 10.11 BDNF CNR1 CRH DRD2 GHRL LEPR
12 liver/biliary system MP:0005370 10.1 ADIPOQ CRH DRD2 LEP LEPR MC4R
13 muscle MP:0005369 10.02 ADIPOQ DRD2 HTR2C LEP LEPR SLC6A3
14 no phenotypic analysis MP:0003012 10.01 BDNF CCK CNR1 CRH DRD2 LEPR
15 renal/urinary system MP:0005367 9.97 ADIPOQ CCK COMT CRH DRD2 LEP
16 neoplasm MP:0002006 9.93 ADIPOQ DRD2 LEP LEPR MC4R POMC
17 reproductive system MP:0005389 9.86 BDNF CNR1 COMT DRD2 LEP LEPR
18 respiratory system MP:0005388 9.76 ADIPOQ BDNF COMT CRH DRD2 LEP
19 skeleton MP:0005390 9.65 ADIPOQ CNR1 CRH DRD2 LEP LEPR
20 taste/olfaction MP:0005394 8.92 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Eating Disorder

Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 293)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Memantine Approved, Investigational Phase 4 19982-08-2 4054
Phentermine Approved, Illicit Phase 4 122-09-8 4771
Norepinephrine Approved Phase 4 51-41-2 439260
Baclofen Approved Phase 4 1134-47-0 2284
leucovorin Approved Phase 4 58-05-9 143 6006
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
Liraglutide Approved Phase 4 204656-20-2 44147092
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Acetaminophen Approved Phase 4 103-90-2 1983
Cycloserine Approved Phase 4 68-41-7 6234 401
Citalopram Approved Phase 4 59729-33-8 2771
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
Cyproheptadine Approved Phase 4 129-03-3 2913
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23 Raclopride Investigational Phase 4 84225-95-6
24 Astringents Phase 4
25 Antidepressive Agents Phase 4
26 Narcotics Phase 4
27 Antidepressive Agents, Second-Generation Phase 4
28 Peripheral Nervous System Agents Phase 4
29 Anti-Obesity Agents Phase 4
30 Narcotic Antagonists Phase 4
31 Psychotropic Drugs Phase 4
32 Adrenergic Agents Phase 4
33 Atomoxetine Hydrochloride Phase 4
34 Anticonvulsants Phase 4
35 Dopamine agonists Phase 4
36 Antiparkinson Agents Phase 4
37 Appetite Depressants Phase 4
38 Hormone Antagonists Phase 4
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
40 Excitatory Amino Acid Antagonists Phase 4
41 Excitatory Amino Acids Phase 4
42 Sympathomimetics Phase 4
43 Autonomic Agents Phase 4
44 Analgesics Phase 4
45 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
46 Duloxetine Hydrochloride Phase 4
47 Tranquilizing Agents Phase 4
48 Dopamine Antagonists Phase 4
49 Antipsychotic Agents Phase 4
50 Lipid Regulating Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 644)
# Name Status NCT ID Phase Drugs
1 Effect of Zinc Supplementation on Appetite and Growth of Primary Malnourished Children Unknown status NCT03098810 Phase 4 Zinc sulphate
2 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
3 Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients Completed NCT00327834 Phase 4 atomoxetine
4 An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity Completed NCT00330655 Phase 4 memantine
5 Effectiveness of Psychological Treatments for BED Completed NCT00060762 Phase 4
6 A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder. Completed NCT00607789 Phase 4 Duloxetine;Placebo
7 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
8 Folic Acid Supplementation for Improving Homocysteine Levels, Cognitive and Depressive Status in Eating Disorders Completed NCT01493674 Phase 4
9 Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children Completed NCT02187952 Phase 4
10 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
11 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
12 Fluoxetine After Weight Restoration in Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
13 A Double-blind, Placebo-controlled, Cross-over Study Using Baclofen in the Treatment of Rumination Syndrome Completed NCT03113396 Phase 4 Baclofen;Placebo oral capsule
14 Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
15 Evaluation of Splanchnic Oximetry,Doppler Flow Velocimetry in the Superior Mesenteric Artery and Feeding Tolerance in VERY LOW BIRTH WEIGHT IUGR and NON-IUGR Infants Receiving Bolus Versus Continuous Enteral Nutrition Completed NCT01341236 Phase 4
16 The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects Completed NCT01739049 Phase 4 Liraglutide
17 Body Contouring - the Analysis of Non-invasive and Invasive Methods and Their Interventional Effects on Quality of Life Completed NCT02151799 Phase 4
18 Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
19 Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
20 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
21 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
22 Comparison of Olanzapine and Lamotrigine in the Prevention of Recurrence of Depressive Episode in the Patients With Bipolar Disorders Completed NCT01864551 Phase 4 Lamotrigine;Olanzapine
23 Attenuation of Corticosteroid Induced Hippocampal Changes Completed NCT01656187 Phase 4 Memantine 10 mg capsule;Memantine-matched Placebo capsule
24 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
25 Combining Lifestyle Modification and Liraglutide to Improve Weight Loss and Health Outcomes Completed NCT02911818 Phase 4 Liraglutide 3.0mg;Placebo Oral Tablet;Phentermine 15 MG
26 The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents Completed NCT02365025 Phase 4
27 Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief Completed NCT00286650 Phase 4
28 Antidepressant Treatment at an Inner City Asthma Clinic Completed NCT01324700 Phase 4 High severity group: Escitalopram;High severity group: Placebo;Low severity group: Escitalopram;Low severity group: Placebo
29 iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children 9 Months to 5 Years 6 Months of Age Recruiting NCT03815019 Phase 4 Megestrol Acetate
30 Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders Not yet recruiting NCT02568007 Phase 4 Cyproheptadine
31 Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
32 Treatment of College Students With ADHD Using OROS Methylphenidate Withdrawn NCT00931398 Phase 4 methylphenidate HCl (Concerta);Placebo
33 Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
34 Feedback Versus no Feedback to Improve Patient Outcome in Group Psychotherapy for Eating Disorders: A Randomised Clinical Trial Unknown status NCT01693237 Phase 2, Phase 3
35 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
36 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
37 Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
38 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3 Armodafinil;Armodafinil;Matching placebo
39 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3 Sodium Oxybate
40 An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder Completed NCT02684279 Phase 3 Dasotraline
41 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3 acamprosate
42 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine
43 A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
44 The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
45 The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
46 A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
47 A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
48 A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving Completed NCT00481975 Phase 3 rimonabant (SR141716)
49 Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder Completed NCT00307619 Phase 3 topiramate
50 Deficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder Completed NCT03717493 Phase 2, Phase 3

Search NIH Clinical Center for Eating Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Paroxetine Hydrochloride
Sertraline Hydrochloride

Cochrane evidence based reviews: feeding and eating disorders

Genetic Tests for Eating Disorder

Anatomical Context for Eating Disorder

MalaCards organs/tissues related to Eating Disorder:

Testes, Brain, Bone, Pituitary, Cortex, Heart, Ovary

Publications for Eating Disorder

Articles related to Eating Disorder:

(show top 50) (show all 17889)
# Title Authors PMID Year
Update on Binge Eating Disorder. 38 17
31078199 2019
31141066 2019
Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma. 17
31192931 2019
Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. 9 38
20339027 2010
Correlation of BDNF blood levels with interoceptive awareness and maturity fears in anorexia and bulimia nervosa patients. 9 38
20195875 2010
Human serotonin transporter expression during megakaryocytic differentiation of MEG-01 cells. 9 38
20041293 2010
The regulatory role of neurotensin on the hypothalamic-anterior pituitary axons: emphasis on the control of thyroid-related functions. 9 38
19878995 2010
The association of catechol-O-methyltransferase genotype with the phenotype of women with eating disorders. 9 38
19852950 2010
Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis. 9 38
19733621 2010
Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding. 9 38
19763327 2009
Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study. 9 38
19801960 2009
Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. 9 38
19741568 2009
Intracerebroventricular administration of leptin increases anxiety-like behavior in female rats after semi-starvation--implications for anxiety in eating disorders. 9 38
19725430 2009
Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. 9 38
19046818 2009
Low serum BDNF and food intake regulation: a possible new explanation of the pathophysiology of eating disorders. 9 38
19152823 2009
Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. 9 38
18728162 2008
Mice overexpressing the 5-hydroxytryptamine transporter show no alterations in feeding behaviour and increased non-feeding responses to fenfluramine. 9 38
18560807 2008
Vagal and hormonal gut-brain communication: from satiation to satisfaction. 9 38
18402643 2008
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. 9 38
18508462 2008
Serotonin transporter binding in eating disorders. 9 38
18165910 2008
Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. 9 38
18199621 2008
Ghrelin and feedback systems. 9 38
17983856 2008
Structure and function of ghrelin. 9 38
18193177 2008
Hormonal alteration in obese adolescents with eating disorder: effects of multidisciplinary therapy. 9 38
18547953 2008
[Cannabinoid system and feeding regulation]. 9 38
18551230 2008
Serotonin transporter binding after recovery from eating disorders. 9 38
17690869 2007
Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa. 9 38
18250619 2007
Nutrition and fertility. 9 38
18043554 2007
Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. 9 38
17376155 2007
Clinical features and physiological response to a test meal in purging disorder and bulimia nervosa. 9 38
17768271 2007
Cannabinoids in eating disorders and obesity. 9 38
17952656 2007
Variations in the preproghrelin gene correlate with higher body mass index, fat mass, and body dissatisfaction in young Japanese women. 9 38
17616759 2007
Roles of leptin and ghrelin in eating disorders? 9 38
17548078 2007
[Genetic polymorphism of COMT in mental disorders]. 9 38
18046978 2007
Leptin and the cardiovascular system: a review. 9 38
18221108 2007
Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: correlations between sympathovagal activity, clinical features, and leptin levels. 9 38
17598965 2007
[Some neurological and psychiatric complications of the disorders of the hypothalamo-hypophyseal system]. 9 38
17437948 2007
Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients. 9 38
18337636 2007
[Leptin and glucose metabolism in eating disorders]. 9 38
17895538 2007
HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. 9 38
17691947 2007
The role of leptin in anorexia nervosa: clinical implications. 9 38
17060920 2007
Possible role of preproghrelin gene polymorphisms in susceptibility to bulimia nervosa. 9 38
16921495 2006
Association of catecholamine-O-methyltransferase and 5-HTTLPR genotype with eating disorder-related behavior and attitudes in females with eating disorders. 9 38
16969275 2006
Plasma agouti-related protein levels in women with anorexia nervosa. 9 38
16904835 2006
Effect of two fasting periods of different duration on ghrelin response to a mixed meal. 9 38
17015184 2006
Eating, sleeping and rewarding: orexin receptors and their antagonists. 9 38
17002215 2006
No change between the serum brain-derived neurotrophic factor in female patients with anorexia nervosa before and after partial weight recovery. 9 38
16753247 2006
The role of neurotensin in central nervous system pathophysiology: what is the evidence? 9 38
16862241 2006
Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. 9 38
16632412 2006
[Brain-derived neurotrophic factor: from nerve growth factor to modulator of brain plasticity in cognitive processes and psychiatric diseases]. 9 38
16078056 2006

Variations for Eating Disorder

Expression for Eating Disorder

Search GEO for disease gene expression data for Eating Disorder.

Pathways for Eating Disorder

Pathways related to Eating Disorder according to KEGG:

# Name Kegg Source Accession
1 Adipocytokine signaling pathway hsa04920
2 cAMP signaling pathway hsa04024

Pathways related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11.79 SLC6A3 DRD2 BDNF
10 11.67 POMC CRHR2 CRH
Show member pathways
Show member pathways
14 10.77 POMC MC4R
15 10.62 CNR1 CCK
16 10.28 POMC CRHR2 CRH

GO Terms for Eating Disorder

Cellular components related to Eating Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 PYY POMC NPY LEP GHRL CRH
2 extracellular region GO:0005576 9.96 PYY POMC NPY LEPR LEP GHRL
3 integral component of plasma membrane GO:0005887 9.95 SLC6A4 SLC6A3 HTR2C HCRTR1 DRD2 CRHR2
4 dendrite GO:0030425 9.63 HTR2C DRD2 CRHR2 COMT CCK BDNF
5 integral component of postsynaptic membrane GO:0099055 9.54 SLC6A4 SLC6A3 DRD2
6 dopaminergic synapse GO:0098691 9.43 SLC6A3 DRD2
7 integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 SLC6A3 DRD2 CNR1
8 axon GO:0030424 9.23 SLC6A3 GHRL DRD2 CRHR2 COMT CNR1

Biological processes related to Eating Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.99 NPY HTR2C HCRTR1 CRH
2 response to hypoxia GO:0001666 9.94 SLC6A4 LEP DRD2 ADIPOQ
3 female pregnancy GO:0007565 9.88 LEP CRH COMT
4 locomotory behavior GO:0007626 9.87 SLC6A3 HTR2C DRD2
5 circadian rhythm GO:0007623 9.87 SLC6A4 LEP ADIPOQ
6 neuropeptide signaling pathway GO:0007218 9.85 PYY POMC NPY HCRTR1
7 response to estrogen GO:0043627 9.84 GHRL CRH COMT
8 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.84 NPY HTR2C CNR1
9 positive regulation of cold-induced thermogenesis GO:0120162 9.84 LEPR LEP GHRL ADIPOQ
10 regulation of blood pressure GO:0008217 9.83 POMC NPY LEP
11 glucose metabolic process GO:0006006 9.83 LEP GHRL ADIPOQ
12 response to nutrient levels GO:0031667 9.83 LEP GHRL ADIPOQ
13 response to nutrient GO:0007584 9.83 SLC6A4 LEP CNR1 ADIPOQ
14 memory GO:0007613 9.81 SLC6A4 CNR1 CCK BDNF
15 response to drug GO:0042493 9.8 SLC6A4 SLC6A3 HTR2C DRD2 CRH COMT
16 response to nicotine GO:0035094 9.77 SLC6A3 DRD2 CNR1
17 positive regulation of multicellular organism growth GO:0040018 9.77 SLC6A3 GHRL DRD2
18 negative regulation of blood pressure GO:0045776 9.75 DRD2 CNR1 ADIPOQ
19 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.73 MC4R DRD2 CRHR2 CNR1
20 G protein-coupled receptor signaling pathway GO:0007186 9.73 PYY POMC NPY MC4R HTR2C HCRTR1
21 response to pain GO:0048265 9.72 CRH COMT
22 synaptic transmission, dopaminergic GO:0001963 9.72 DRD2 CRH
23 response to iron ion GO:0010039 9.72 SLC6A3 DRD2
24 glucose homeostasis GO:0042593 9.72 POMC LEPR LEP CNR1 ADIPOQ
25 prepulse inhibition GO:0060134 9.71 SLC6A3 DRD2
26 negative regulation of gluconeogenesis GO:0045721 9.71 LEPR ADIPOQ
27 dopamine metabolic process GO:0042417 9.71 DRD2 COMT
28 regulation of synaptic transmission, GABAergic GO:0032228 9.71 DRD2 CNR1
29 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A4 SLC6A3
30 central nervous system neuron development GO:0021954 9.7 NPY LEP
31 sexual reproduction GO:0019953 9.69 LEPR LEP
32 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.69 GHRL DRD2
33 positive regulation of growth hormone secretion GO:0060124 9.68 GHRL DRD2
34 negative regulation of appetite GO:0032099 9.68 LEP CCK
35 monoamine transport GO:0015844 9.68 SLC6A4 SLC6A3
36 leptin-mediated signaling pathway GO:0033210 9.68 LEPR LEP
37 adenohypophysis development GO:0021984 9.67 SLC6A3 DRD2
38 dopamine catabolic process GO:0042420 9.67 SLC6A3 COMT
39 response to cocaine GO:0042220 9.67 SLC6A3 DRD2 CRH CNR1
40 regulation of bone remodeling GO:0046850 9.65 LEPR LEP
41 energy reserve metabolic process GO:0006112 9.65 MC4R LEPR LEP
42 positive regulation of behavioral fear response GO:2000987 9.64 CRH CCK
43 regulation of metabolic process GO:0019222 9.63 MC4R LEP
44 regulation of appetite GO:0032098 9.63 POMC HTR2C
45 regulation of feeding behavior GO:0060259 9.63 MC4R LEPR CNR1
46 response to ethanol GO:0045471 9.63 SLC6A3 LEP DRD2 CRH CNR1 ADIPOQ
47 positive regulation of cortisol secretion GO:0051464 9.62 GHRL CRH
48 positive regulation of corticotropin secretion GO:0051461 9.62 GHRL CRH
49 negative regulation of glucagon secretion GO:0070093 9.61 LEP CRH
50 positive regulation of appetite GO:0032100 9.61 NPY GHRL

Molecular functions related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.95 NPY MC4R HTR2C HCRTR1 DRD2 CRHR2
2 signaling receptor binding GO:0005102 9.7 SLC6A3 POMC NPY LEP DRD2 CRH
3 drug binding GO:0008144 9.67 SLC6A3 HTR2C DRD2 CNR1
4 G protein-coupled receptor binding GO:0001664 9.62 PYY POMC NPY GHRL
5 peptide hormone binding GO:0017046 9.56 MC4R LEPR HCRTR1 CRHR2
6 neurotransmitter:sodium symporter activity GO:0005328 9.51 SLC6A4 SLC6A3
7 dopamine binding GO:0035240 9.49 SLC6A3 DRD2
8 serotonin binding GO:0051378 9.48 SLC6A4 HTR2C
9 peptide hormone receptor binding GO:0051428 9.46 LEP CCK
10 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A4 SLC6A3
11 neuropeptide hormone activity GO:0005184 9.26 PYY NPY CRH CCK
12 hormone activity GO:0005179 9.23 PYY POMC NPY LEP GHRL CRH

Sources for Eating Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....